|
|
|
NeuroStar TMS Therapy® Clinical Research
Clinical trials have proven the efficacy of NeuroStar TMS Therapy in treating patients with major depression
who have had not benefited from prior antidepressant medication. In clinical trials the NeuroStar TMS Therapy
system was shown to significantly improve patient scores on the Montgomery Asberg Depression
Rating Scale (MADRS) and Hamilton Depression Rating Scale (HAMD-24) scale
after 4-6 weeks of treatment.
NeuroStar TMS Therapy was studied in adult patients suffering from Major Depressive
Disorder; all of whom had achieved little to no success with previous antidepresant medication therapy.
The chart below is a brief description of the indicated patient population:2
Click to enhance
NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode. In clinical trials, the indicated population had been treated with at least four medication treatment attempts, one of which was at an adequate dose and duration.Click here for full prescribing and safety information
NeuroStar TMS Therapy has not been studied in patients who have not received prior
antidepressant treatment. Efficacy has not been established in patients who have
failed to receive benefit from two or more prior antidepressant medications at minimal
effective dose and duration in the current episode.
An Effective Option for Treating Major Depressive Disorder
Demonstrated Acute MDD Efficacy in Randomized, Controlled Trial
- 164 patients from indication patient population
- Triple-blinded (treater, rater, and patient)
- 4-6 weeks of TMS monotherapy
Patients treated with active NeuroStar TMS Therapy® experienced an
average reduction in their depression symptoms of 22.1% compared to a 9% average
reduction of depression symptoms in patients receiving inactive treatment2.
NeuroStar® treated patients also experienced significant improvement
in anxiety and other symptoms associated with depression such as appetite changes, aches and pains, and lack of energy.
Acute MDD Efficacy Results in Open-Label Clinical Trial1
- 43 patients from indicated patient population
- 6 weeks of TMS monotherapy
Approximately half of the patients treated with NeuroStar TMS Therapy®
experienced significant improvement in depression symptoms. About a third of the
patients treated with NeuroStar TMS Therapy® experienced complete
symptom relief at the end of six weeks.
View safety data
References:
- Demitrack MA, Thase, ME. Clinical significance of transcranial magnetic stimulation
(TMS) in the treatment of pharmacoresistant depression: synthesis of recent data.
Psychopharm Bull. 2009, 42(2): 5-38.
- Data on File
|
|
 |
|
Refer a Patient for Treatment
|
NeuroStar TMS Therapy may be right for your patients suffering from major depression. Refer them here.
Find a Provider
|
|
|
|
Become a NeuroStar TMS Therapy Provider
|
Provide your patients the new way back from depression with NeuroStar TMS Therapy®.
Contact us to find out how you can bring NeuroStar into your workplace.
Contact Us
|
|
|
*
NeuroStar TMS Therapy ® is indicated for the treatment of Major Depressive
Disorder in adult patients who have failed to achieve satisfactory improvement from
one prior antidepressant medication at or above the minimal effective dose and duration
in the current episode. Click here for full prescribing and safety information
|